Advancements in Personalized Cancer Vaccines
Summary:
Scientists have made significant progress in developing personalized cancer vaccines that train the immune system to target individual tumors, paving the way for more effective cancer therapies.
Biopharma Megamergers and Funding Trends at JPM25
Summary:
At JPM25, experts predicted a rise in megamergers, a shift to smaller Series A funding rounds, and potential consolidation among struggling small biotechs due to funding challenges.
CRISPR-Based Diagnostic Test for Infectious Diseases
Summary:
Researchers have developed a CRISPR-based diagnostic test capable of rapidly detecting multiple infectious diseases with high accuracy, potentially transforming disease diagnosis and management.
What Trump 2.0 Means for Science: The Likely Winners and Losers
Summary:
As President Trump begins his second term, technology sectors like artificial intelligence and space exploration anticipate favorable policies, while environmental and biomedical sciences face potential funding cuts and regulatory rollbacks.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Summary:
2025 kicks off with robust pharma M&A activity, highlighted by J&J’s $14.6B intra-cellular deal. The industry holds $1.3T in deal potential, though high premiums and margin pressures may impact future transactions.
